DiaMedica Therapeutics : Annual report pursuant to Section 13 and 15(d) Related Documents EX-4.1 EX-4.8 EX-10.19 EX-21.1 EX-23.1 EX-31.1 EX-31.2 EX-32.1 EX-32.2 - Marketscreener.com

DiaMedica Therapeutics : Annual report pursuant to Section 13 and 15(d) Related Documents EX-4.1 EX-4.8 EX-10.19 EX-21.1 EX-23.1 EX-31.1 EX-31.2 EX-32.1 EX-32.2  Marketscreener.com

Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more